Company Quick10K Filing
Beigene
Closing Price ($) Shares Out (MM) Market Cap ($MM)
$0.00 784 $98,573
10-K 2020-03-02 Annual: 2019-12-31
10-Q 2019-11-12 Quarter: 2019-09-30
10-Q 2019-08-08 Quarter: 2019-06-30
10-Q 2019-05-09 Quarter: 2019-03-31
10-K 2019-02-28 Annual: 2018-12-31
10-Q 2018-11-08 Quarter: 2018-09-30
10-Q 2018-08-09 Quarter: 2018-06-30
10-Q 2018-05-09 Quarter: 2018-03-31
10-K 2018-02-28 Annual: 2017-12-31
10-Q 2017-11-13 Quarter: 2017-09-30
10-Q 2017-08-09 Quarter: 2017-06-30
10-Q 2017-05-10 Quarter: 2017-03-31
10-K 2017-03-22 Annual: 2016-12-31
10-Q 2016-11-10 Quarter: 2016-09-30
10-Q 2016-08-10 Quarter: 2016-06-30
10-Q 2016-05-12 Quarter: 2016-03-31
10-K 2016-03-30 Annual: 2015-12-31
8-K 2020-03-25 Regulation FD, Other Events, Exhibits
8-K 2020-03-17 Enter Agreement, Sale of Shares, Exhibits
8-K 2020-03-02 Earnings, Regulation FD, Other Events, Exhibits
8-K 2020-01-24 Other Events, Exhibits
8-K 2020-01-21 Other Events, Exhibits
8-K 2020-01-12 Regulation FD, Exhibits
8-K 2020-01-02 Sale of Shares, Officers, Regulation FD, Other Events, Exhibits, Exhibits
8-K 2019-12-27 Shareholder Vote
8-K 2019-12-22 Other Events, Exhibits
8-K 2019-12-12 Regulation FD, Other Events, Exhibits
8-K 2019-12-08 Other Events, Exhibits
8-K 2019-12-06 Enter Agreement, Sale of Shares
8-K 2019-11-23 Other Events, Exhibits
8-K 2019-11-14 Other Events, Exhibits
8-K 2019-11-12 Earnings, Other Events, Exhibits
8-K 2019-11-05 Other Events, Exhibits
8-K 2019-10-31 Enter Agreement, Sale of Shares, Regulation FD, Exhibits
8-K 2019-09-30 Other Events, Exhibits
8-K 2019-09-24 Other Events, Exhibits
8-K 2019-09-12 Regulation FD
8-K 2019-08-21 Other Events, Exhibits
8-K 2019-08-08 Earnings, Regulation FD, Other Events, Exhibits
8-K 2019-06-20 Regulation FD, Other Events, Exhibits
8-K 2019-06-17 Leave Agreement, Regulation FD, Other Events, Exhibits
8-K 2019-06-05 Shareholder Vote, Other Events, Exhibits
8-K 2019-06-03 Other Events, Exhibits
8-K 2019-05-09 Earnings, Other Events, Exhibits
8-K 2019-04-09 Other Events, Exhibits
8-K 2019-04-02 Other Events, Exhibits
8-K 2019-03-06 Other Events, Exhibits
8-K 2019-02-27 Earnings, Regulation FD, Other Events, Exhibits
8-K 2019-01-23 Officers
8-K 2019-01-14 Other Events, Exhibits
8-K 2019-01-06 Regulation FD, Exhibits
8-K 2018-12-19 Leave Agreement
8-K 2018-12-15 Leave Agreement, Other Events, Exhibits
8-K 2018-12-11 Shareholder Rights, Officers, Amend Bylaw, Shareholder Vote, Exhibits
8-K 2018-12-01 Other Events, Exhibits
8-K 2018-11-27 Other Events, Exhibits
8-K 2018-11-16 Other Events, Exhibits
8-K 2018-11-07 Earnings, Other Events, Exhibits
8-K 2018-10-22 Other Events, Exhibits
8-K 2018-10-12 Other Events, Exhibits
8-K 2018-09-20 Other Events, Exhibits
8-K 2018-08-31 Other Events, Exhibits
8-K 2018-08-26 Other Events, Exhibits
8-K 2018-08-08 Earnings, Other Events, Exhibits
8-K 2018-08-07 Officers, Other Events, Exhibits
8-K 2018-08-02 Enter Agreement, Other Events, Exhibits
8-K 2018-07-29 Other Events
8-K 2018-07-27 Enter Agreement, Other Events, Exhibits
8-K 2018-07-24 Earnings, Other Events, Exhibits
8-K 2018-07-22 Enter Agreement, Other Events, Exhibits
8-K 2018-06-15 Other Events, Exhibits
8-K 2018-06-06 Officers, Shareholder Vote, Other Events, Exhibits
8-K 2018-05-17 Other Events, Exhibits
8-K 2018-05-09 Earnings, Other Events, Exhibits
8-K 2018-04-30 Officers, Other Events, Exhibits
8-K 2018-04-16 Other Events, Exhibits
8-K 2018-04-10 Other Events, Exhibits
8-K 2018-04-01 Officers, Other Events, Exhibits
8-K 2018-02-28 Earnings, Other Events, Exhibits
8-K 2018-02-09 Other Events, Exhibits
8-K 2018-02-05 Other Events, Exhibits
8-K 2018-01-31 Other Events, Exhibits
8-K 2018-01-17 Enter Agreement, Other Events, Exhibits
8-K 2018-01-16 Earnings, Other Events, Exhibits
8-K 2018-01-09 Other Events, Exhibits
8-K 2018-01-07 Regulation FD, Other Events, Exhibits
8-K 2018-01-02 Other Events, Exhibits

Beigene Financials

BGNE Metrics, Comps, Filings

Annual | Quarterly

Business

We are a commercial-stage biotechnology company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer. Our internally-developed lead drug candidates are currently in late-stage clinical trials, including 21 registration or registration-enabling trials in 14 discrete cancer indications. We have submitted three new drug applications for regulatory approval in China and are planning for new drug launches and additional submissions in China and the United States in 2019 and 2020. In addition, we are marketing three in-licensed cancer drugs in China from which we have been generating product revenue since September 2017.

We started as a research and development company in Beijing in 2010, focusing on developing best-in-class oncology drugs. Over the last nine years, we have developed into a fully-integrated global biotechnology company with operations in China, the United States, Europe and Australia, including a more than 800-person global clinical development team running over 50 ongoing or planned clinical trials as of January 24, 2019. We also have a growing commercial team that is selling our existing in-licensed drugs in China and preparing for launches of our internally-developed drug candidates in China and the United States, as well as internal manufacturing capabilities in China that are operational or under construction for the clinical and commercial supply of our small molecule and biologic drug candidates.

Our lead internally-developed drug candidates include the following:


Valuation ($BB)

Market Cap, Enterprise Value

Balance Sheet ($BB)

Assets, Stockholders' Equity

Income Statement ($BB Quarterly)

Revenue, Gross Profit, Net Income

Cash Flow ($BB Quarterly)

Operating, Investing, Financing

Comps ($MM TTM) Market Cap Gross Margin EV/EBITDA Ret on Assets Assets Liabilities Revenue G Profit Net Income EBITDA EV
Abbott (ABT) 149,317 57% 26.2 5% 68,539 36,722 31,355 17,879 3,292 6,255 164,119
Eli Lilly (LLY) 105,897 78% 12.7 21% 37,893 34,431 22,644 17,612 7,948 9,419 119,560
AbbVie (ABBV) 109,786 77% 21.1 5% 59,441 67,667 32,867 25,412 3,255 6,259 132,264
Beigene (BGNE) 100,124 74% -123.1 -44% 1,881 587 430 318 -827 -807 99,328
Bristol Myers Squibb (BMY) 82,160 70% 10.6 10% 57,433 39,679 24,173 16,837 5,680 7,151 76,061
Celgene (CELG) 72,111 96% 10.4 14% 41,363 29,276 16,982 16,354 5,880 7,734 80,796
GW Pharmaceuticals (GWPH) 45,954 89% -870.1 -8% 848 128 205 182 -64 -52 45,400
Allergan (AGN) 54,957 63% -241.2 -5% 122,925 38,486 15,818 9,949 -5,872 -316 76,270
Zoetis (ZTS) 60,799 51% 29.1 13% 11,272 8,594 6,150 3,124 1,461 2,252 65,484
Sanofi (SNY) 52,845 0% 111,408 0 0 0 0 52,184
Vertex Pharmaceuticals (VRTX) 43,431 87% 46.7 29% 7,515 2,261 3,620 3,135 2,144 857 40,027
Regeneron Pharmaceuticals (REGN) 32,266 0% 12.2 15% 13,939 3,435 7,622 0 2,144 2,539 30,869
Alexion Pharmaceuticals (ALXN) 23,581 92% 12.8 10% 14,815 4,448 4,736 4,359 1,470 1,874 23,912
Biomarin Pharmaceutical (BMRN) 12,700 79% 1,194.1 -1% 4,558 1,484 1,250 986 -39 11 13,147
Elanco Animal Health (ELAN) 9,964 52% 30.6 1% 8,824 3,336 3,083 1,611 94 393 12,004
Mylan (MYL) 10,768 34% 12.5 -0% 31,054 19,590 8,309 2,810 -4 1,882 23,458
Teva (TEVA) 7,142 43% -10.6 -7% 57,246 42,322 17,455 7,550 -3,961 -2,814 29,713
Sarepta Therapeutics (SRPT) 5,588 0% -7.9 -36% 1,702 707 365 0 -620 -576 4,529
Ionis Pharmaceuticals (IONS) 8,784 76% 17.4 15% 2,895 1,397 821 626 436 491 8,536
Sage Therapeutics (SAGE) 7,414 82% -10.7 -56% 1,204 123 5 4 -670 -670 7,152

Balance Sheet ($MM)2016-03-312016-06-302016-09-302016-12-312017-03-312017-06-302017-09-302017-12-312018-03-312018-06-302018-09-302018-12-312019-03-312019-06-302019-09-30
Cash20958868898261209240508470711741788943901
Accounts Receivable112923333741595856
Inventory611762016134938
PP&E81017263134556393108130157198213226
Assets2652512354063774741,0491,0461,7091,6542,4092,2502,1722,1501,881
Accounts Payable4671220243570538686113105149112
Long-Term Debt18196150508693105
Liabilities2231485368204285362350427425496550579587
Stockholders' Equity2432201883533082567506701,3441,2131,9701,7391,6091,5541,278
Income Statement ($MM)2016-03-312016-06-302016-09-302016-12-312017-03-312017-06-302017-09-302017-12-312018-03-312018-06-302018-09-302018-12-312019-03-312019-06-302019-09-30
Revenue100022018335354597824350
Cost of Revenue569151820
Gross Profit2847456322630
R&D1821302943608891110186148178229237
SG&A345891516272958495882105
Tax000-000-3280120181
Net Income-22-24-35-38-51-61117-99-105-157-144-267-168-86-307
Cash Flow ($MM)2016-03-312016-06-302016-09-302016-12-312017-03-312017-06-302017-09-302017-12-312018-03-312018-06-302018-09-302018-12-312019-03-312019-06-302019-09-30
Cash Operating-20-19-24-26-36794-105-117-132-172-46-265
Cash Investing40-13644-17144-401-68-39434-491172192214
Cash Financing170581993340376447871431525